

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023659 A1

(51) International Patent Classification:

C12N 15/117 (2010.01) *A61K 47/68* (2017.01)
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61K 47/64 (2017.01)

(21) International Application Number:

PCT/US2022/075236

(22) International Filing Date:

19 August 2022 (19.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/235,656	20 August 2021 (20.08.2021)	US
63/236,809	25 August 2021 (25.08.2021)	US
63/255,318	13 October 2021 (13.10.2021)	US

(71) Applicant: **TALLAC THERAPEUTICS, INC.** [US/US];
866 Malcolm Road, Suite 100, Burlingame, California
94010 (US).

(72) Inventors: **STROP, Pavel**; c/o Tallac Therapeutics, Inc.,
866 Malcolm Road, Suite 100, Burlingame, California
94010 (US). **AN, Mingrui**; c/o Tallac Therapeutics, Inc.,
866 Malcolm Road, Suite 100, Burlingame, California
94010 (US). **COSTA, Maria José da Silva Teixeira**; c/
o Tallac Therapeutics, Inc., 866 Malcolm Road, Suite 100,
Burlingame, California 94010 (US). **WAN, Hong Iris**; c/
o Tallac Therapeutics, Inc., 866 Malcolm Road, Suite 100,
Burlingame, California 94010 (US). **BONACORSI, Maja
Zukic**; c/o Tallac Therapeutics, Inc., 866 Malcolm Road,
Suite 100, Burlingame, California 94010 (US). **CHEN,
Amy Shaw-Ru**; c/o Tallac Therapeutics, Inc., 866 Mal-

colm Road, Suite 100, Burlingame, California 94010 (US).
SIM, Bang Janet; c/o Tallac Therapeutics, Inc., 866 Mal-
colm Road, Suite 100, Burlingame, California 94010 (US).
LI, Min; c/o Tallac Therapeutics, Inc., 866 Malcolm Road,
Suite 100, Burlingame, California 94010 (US). **KUO, Tra-
cy Chia-Chien**; c/o Tallac Therapeutics, Inc., 866 Mal-
colm Road, Suite 100, Burlingame, California 94010 (US).
SANGALANG, Emma Ruth B.; c/o Tallac Therapeutics,
Inc., 866 Malcolm Road, Suite 100, Burlingame, California
94010 (US).


(74) Agent: **FRAUSTO, Stephen Diego** et al.; Morrison &
Foerster LLP, 755 Page Mill Road, Palo Alto, California
94304-1018 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NECTIN-4 ANTIBODIES AND CONJUGATES

FIG. 9A. Engineered Q-tag



(57) Abstract: The present disclosure provides nectin-4 antibodies
and oligonucleotide conjugates thereof. Also provided are related
methods of preparation thereof and methods of use thereof, includ-
ing therapeutic uses.

WO 2023/023659 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*